15 July 2024
Hogan Lovells advises HLS Therapeutics on the sale of its XENPOZYME® Royalty Interest
Advising firms
Deal team
8 lawyers named| Lawyer | Firm | Seniority | Practice | Office |
|---|---|---|---|---|
| Gabi Witt Lead | Hogan Lovells Cadwalader | Partner | Not stated | Washington, D.C. |
| Stephen Nicolai Lead | Hogan Lovells Cadwalader | Partner | Not stated | Philadelphia |
| Spenser Karr | Hogan Lovells Cadwalader | Senior associate | Not stated | Philadelphia |
| Scott Friedman | Hogan Lovells Cadwalader | Partner | Not stated | New York |
| Edward Purdon | Hogan Lovells Cadwalader | Partner | Not stated | Washington, D.C. |
| William Regan | Hogan Lovells Cadwalader | Partner | Not stated | New York |
| Brooke Shekhar | Hogan Lovells Cadwalader | Counsel | Not stated | Washington, D.C. |
| Amy Isselmann | Hogan Lovells Cadwalader | Trainee | Not stated | Philadelphia |
5 more lawyers on this deal. Register free to see the full deal team, with seniority, practice and office.
REGISTER FREE SIGN INWant co-counsel patterns, repeat clients and alerts when these firms land their next deal? Get Pro.
Stated terms
- Stated value
- USD 45.8m (US$45.75 million)
- What the figure measures
- Total transaction value
- Client
- HLS Therapeutics Inc.Sell-side
- Counterparties
- DRI Healthcare Trust (Buy-side)